RXDX-105: Interim Phase I data

Interim data from 11 evaluable patients with advanced or metastatic solid tumors with RET or BRAF alterations in an

Read the full 198 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE